Endosense Overview
- Founded
-
2003
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$320M
Endosense General Information
Description
Developer of technology for contact-force measurement in catheter ablation. The company focuses on improving the efficacy, safety and accessibility of catheter ablation for the treatment of cardiac arrhythmias. The company pioneered the use of contact force measurement in catheter ablation with the development of the TactiCath, the industry's first force-sensing ablation catheter.
Contact Information
Primary Industry
Surgical Devices
Acquirer
Primary Office
- Chemin du Grand-Puits 42
- 1217 Meyrin
- Switzerland
+41 022 000 00 00
Endosense Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 19-Aug-2013 | $320M | 00000 | 00000 | Completed | Generating Revenue |
| 3. Later Stage VC (Series C) | 05-Mar-2013 | 000.00 | 00000 | Completed | Generating Revenue | |
| 2. Later Stage VC (Series B) | 01-Sep-2009 | $36M | $56M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 21-Nov-2005 | $20M | $20M | Completed | Product Development |
Endosense Former Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 3i Group | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Andera Partners | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| DEFI Gestion | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| Gimv | PE/Buyout | Minority | 000 0000 | 000000 0 | |
| NGN Capital | Venture Capital | Minority | 000 0000 | 000000 0 |